Cargando…

A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis

BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuetz, C. Andy, Alperin, Peter, Guda, Swathi, van Herick, Andrew, Cariou, Bertrand, Eddy, David, Gumprecht, Janusz, Nicolucci, Antonio, Schwarz, Peter, Wareham, Nick J., Witte, Daniel R., Smith, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712021/
https://www.ncbi.nlm.nih.gov/pubmed/23869204
http://dx.doi.org/10.1371/journal.pone.0066454
_version_ 1782277003078008832
author Schuetz, C. Andy
Alperin, Peter
Guda, Swathi
van Herick, Andrew
Cariou, Bertrand
Eddy, David
Gumprecht, Janusz
Nicolucci, Antonio
Schwarz, Peter
Wareham, Nick J.
Witte, Daniel R.
Smith, Ulf
author_facet Schuetz, C. Andy
Alperin, Peter
Guda, Swathi
van Herick, Andrew
Cariou, Bertrand
Eddy, David
Gumprecht, Janusz
Nicolucci, Antonio
Schwarz, Peter
Wareham, Nick J.
Witte, Daniel R.
Smith, Ulf
author_sort Schuetz, C. Andy
collection PubMed
description BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-specific data from Denmark, France, Germany, Italy, Poland, and the United Kingdom to generate simulated populations of individuals aged 40–75 eligible for health checks in those countries (e.g. individuals without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease). For each country, we used the Archimedes model to compare seven health check strategies consisting of assessments for diabetes, hypertension, lipids, and smoking. For patients diagnosed with vascular disease, treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). RESULTS: Compared with current care, health checks reduced the incidence of MACE (6–17 events prevented per 1000 people screened) and diabetes related microvasular complications (5–11 events prevented per 1000 people screened), and increased QALYs (31–59 discounted QALYs) over 30 years, in all countries. The cost per QALY of offering a health check to all individuals in the study cohort ranged from €14903 (France) to cost saving (Poland). Pre-screening the population and offering health checks only to higher risk individuals lowered the cost per QALY. Pre-screening on the basis of obesity had a cost per QALY of €10200 (France) or less, and pre-screening with a non-invasive risk score was similar. CONCLUSIONS: A vascular disease health check would likely be cost effective at 30 years in Denmark, France, Germany, Italy, Poland, and the United Kingdom.
format Online
Article
Text
id pubmed-3712021
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37120212013-07-18 A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis Schuetz, C. Andy Alperin, Peter Guda, Swathi van Herick, Andrew Cariou, Bertrand Eddy, David Gumprecht, Janusz Nicolucci, Antonio Schwarz, Peter Wareham, Nick J. Witte, Daniel R. Smith, Ulf PLoS One Research Article BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-specific data from Denmark, France, Germany, Italy, Poland, and the United Kingdom to generate simulated populations of individuals aged 40–75 eligible for health checks in those countries (e.g. individuals without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease). For each country, we used the Archimedes model to compare seven health check strategies consisting of assessments for diabetes, hypertension, lipids, and smoking. For patients diagnosed with vascular disease, treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). RESULTS: Compared with current care, health checks reduced the incidence of MACE (6–17 events prevented per 1000 people screened) and diabetes related microvasular complications (5–11 events prevented per 1000 people screened), and increased QALYs (31–59 discounted QALYs) over 30 years, in all countries. The cost per QALY of offering a health check to all individuals in the study cohort ranged from €14903 (France) to cost saving (Poland). Pre-screening the population and offering health checks only to higher risk individuals lowered the cost per QALY. Pre-screening on the basis of obesity had a cost per QALY of €10200 (France) or less, and pre-screening with a non-invasive risk score was similar. CONCLUSIONS: A vascular disease health check would likely be cost effective at 30 years in Denmark, France, Germany, Italy, Poland, and the United Kingdom. Public Library of Science 2013-07-15 /pmc/articles/PMC3712021/ /pubmed/23869204 http://dx.doi.org/10.1371/journal.pone.0066454 Text en © 2013 Schuetz et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Schuetz, C. Andy
Alperin, Peter
Guda, Swathi
van Herick, Andrew
Cariou, Bertrand
Eddy, David
Gumprecht, Janusz
Nicolucci, Antonio
Schwarz, Peter
Wareham, Nick J.
Witte, Daniel R.
Smith, Ulf
A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title_full A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title_fullStr A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title_full_unstemmed A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title_short A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis
title_sort standardized vascular disease health check in europe: a cost-effectiveness analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712021/
https://www.ncbi.nlm.nih.gov/pubmed/23869204
http://dx.doi.org/10.1371/journal.pone.0066454
work_keys_str_mv AT schuetzcandy astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT alperinpeter astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT gudaswathi astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT vanherickandrew astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT carioubertrand astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT eddydavid astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT gumprechtjanusz astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT nicolucciantonio astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT schwarzpeter astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT warehamnickj astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT wittedanielr astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT smithulf astandardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT schuetzcandy standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT alperinpeter standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT gudaswathi standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT vanherickandrew standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT carioubertrand standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT eddydavid standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT gumprechtjanusz standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT nicolucciantonio standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT schwarzpeter standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT warehamnickj standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT wittedanielr standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis
AT smithulf standardizedvasculardiseasehealthcheckineuropeacosteffectivenessanalysis